Get to know our clinical trials

Phase I/II clinical trial of the selective PARP1 inhibitor, IMP1734, in participants with advanced solid tumors.

THE MAIN OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EXTENT TO WHICH IMP1734 IS TOLERATED, ALONE AND IN COMBINATION WITH OTHER ANTICANCER DRUGS, AS A TREATMENT FOR PATIENTS WITH OVARIAN, BREAST, PROSTATE AND PANCREATIC CANCER.

Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • FIRST HUMAN, PHASE I/II, UNBLINDED, MULTICENTER, MULTICENTER, STEPWISE DOSE ESCALATION, DOSE OPTIMIZATION AND DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF THE SELECTIVE PARP1 INHIBITOR, "IMP1734", IN PATIENTS WITH ADVANCED SOLID TUMORS.
  • Code EudraCT: 2023-509230-19
  • Protocol number: EIK1003-001
  • Promoter: Eikon Therapeutics
  • Molecule/Drug: IMP1734
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.